Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HU6 in Healthy Volunteers
NCT04463017Phase 1Completed
- Sponsor
- Rivus Pharmaceuticals, Inc.
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing HU6 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration at 3 months and Area Under the Curve at 3 months. Started Aug 2020; status: completed.
02
Drugs
HU6
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04463017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04463017.